PharmaJet®, the maker of innovative, needle-free injection technology, and Mundipharma announced an exclusive partnership for the multinational healthcare organization to market and distribute PharmaJet's Tropis® and Stratis® needle-free devices across more than 120 markets worldwide.

Tropis® (ID) and Stratis® (IM/SC) devices are both optimized for vaccine immunizations. The Tropis® device has been shown in multiple studies to deliver a superior immune response after 2 fIPV doses and uniquely enables mass-scale fractional dose poliovirus vaccine injections at a lower total cost than intramuscular injection.

PharmaJet has a multi-year agreement with the World Health Organization (WHO) to provide its Needle-free technology for use in the global effort to eradicate polio.

With a vertically integrated R&D-to-distribution pipeline, Mundipharma has a strong track record of building successful alliances with industry partners to license, market and distribute solutions that improve patients' lives, while also providing options for financially constrained healthcare systems.